Regeneron Pharmaceuticals, Inc. Furnishes Preliminary Financial Estimates
Summary
Regeneron Pharmaceuticals, Inc. expects to include an acquired in-process research and development (IPR&D) charge of approximately $127 million on a pre-tax basis in its second quarter 2026 financial results. This charge relates to up-front and opt-in payments for collaboration and licensing agreements. The company anticipates this will negatively impact both GAAP and non-GAAP net income per diluted share for by approximately $1.00. These preliminary estimates are subject to finalization and may differ from actual results.
Why It Matters
Investors should note the expected $127 million pre-tax IPR&D charge and its anticipated negative impact of approximately $1.00 on GAAP and non-GAAP net income per diluted share for Q2 2026, signaling a material financial event affecting profitability.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how REGN traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View REGN Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“to negatively impact each of GAAP and non-GAAP net income per diluted share for the second quarter 2026 by approximately $1.00.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000872589
- Filing Date
- Monday, July 6, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive